Research Purposes Only. NOT FOR HUMAN CONSUMPTION
CJC-1295 with DAC dosage for growth hormone research is a widely discussed topic in peptide science, particularly in studies focused on hormone optimization, recovery, and body composition. CJC-1295 (With DAC) is a long-acting analog of growth hormone-releasing hormone (GHRH) designed to stimulate sustained release of growth hormone (GH) over an extended period.
The addition of DAC (Drug Affinity Complex) significantly extends the peptide’s half-life, allowing for less frequent dosing compared to shorter-acting GHRH peptides. This makes it especially valuable in structured research protocols where consistent GH elevation is desired.
In this guide, we will explore CJC-1295 with DAC dosage for growth hormone research, including its mechanism of action, usage protocols, benefits, cycle structure, and safety considerations.
CJC-1295 (With DAC) is a synthetic peptide designed to stimulate the natural production of growth hormone.
The DAC version is preferred in research requiring stable GH levels over time.
CJC-1295 stimulates the pituitary gland to release growth hormone.
Unlike direct GH administration, it works through the body’s natural hormone signaling system.
When discussing CJC-1295 with DAC dosage for growth hormone research, weekly dosing protocols are typically used due to its extended half-life.
CJC-1295 is widely studied for its ability to enhance GH and IGF-1 levels.
By increasing GH, CJC-1295 indirectly boosts IGF-1 levels.
Provides long-lasting hormone stimulation.
Supports anabolic and recovery pathways.
Weekly dosing improves protocol simplicity.
Improves tissue repair and regeneration.
Works through physiological pathways.
| Phase | Duration |
|---|---|
| Initiation | 2 weeks |
| Active | 6–10 weeks |
| Rest | 2–4 weeks |
CJC-1295 may produce mild effects in research settings.
CJC-1295 is often studied alongside other peptides.
